Impact of treatment with recombinant human GH and IGF-I on visceral adipose tissue and glucose homeostasis in adults

Kevin C J Yuen, David B. Dunger

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Supraphysiological doses of growth hormone (GH) therapy are generally thought to antagonize the effects of insulin, whereas the insulin-like growth factor I (IGF-I) potentiates insulin-like actions. Paradoxically, adults with GH deficiency and patients with acromegaly are both predisposed to glucose intolerance and insulin resistance; however, one cannot extrapolate from these pathological conditions to determine the true metabolic roles of GH and IGF-I in glucose homeostasis. Growth hormone also promotes lipolysis, which has been shown to be the principal determinant of its insulin-antagonistic properties; on the other hand, IGF-I, which acts as an insulin sensitizer, does not exert any direct effect on lipolysis or lipogenesis. Under physiological conditions, the insulin-sensitizing effect of IGF-I is evident only after feeding, when the bioavailability of circulating IGF-I is increased. In contrast to supraphysiological GH doses, low doses of GH treatment have been shown to increase circulating IGF-I levels and IGF-I bioavailability and, thus, may theoretically enhance insulin sensitivity without inducing lipolysis. We have recently reported that a fixed administration of a very low GH dose (1.7 μg/kg/day or 0.1 mg/day) improved insulin sensitivity in adults with GH deficiency and increased peripheral glucose uptake in subjects with impaired glucose tolerance and the metabolic syndrome. Our data raise the possibility that this very low GH dose may play a role in maintaining β-cell function and possibly delay the progression to type 2 diabetes in these high-risk patients.

Original languageEnglish (US)
Pages (from-to)55-61
Number of pages7
JournalGrowth Hormone and IGF Research
Volume16
Issue numberSUPPL.
DOIs
StatePublished - Jul 2006

Fingerprint

Intra-Abdominal Fat
Human Growth Hormone
Insulin-Like Growth Factor I
Growth Hormone
Homeostasis
Glucose
Insulin
Lipolysis
Insulin Resistance
Glucose Intolerance
Therapeutics
Biological Availability
Lipogenesis
Acromegaly
Type 2 Diabetes Mellitus

Keywords

  • Growth hormone
  • Growth hormone deficient adults
  • Insulin sensitivity
  • Insulin-like growth factor I
  • Metabolic syndrome

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Impact of treatment with recombinant human GH and IGF-I on visceral adipose tissue and glucose homeostasis in adults. / Yuen, Kevin C J; Dunger, David B.

In: Growth Hormone and IGF Research, Vol. 16, No. SUPPL., 07.2006, p. 55-61.

Research output: Contribution to journalArticle

@article{924464969b4a4b2899e209f13d0437b5,
title = "Impact of treatment with recombinant human GH and IGF-I on visceral adipose tissue and glucose homeostasis in adults",
abstract = "Supraphysiological doses of growth hormone (GH) therapy are generally thought to antagonize the effects of insulin, whereas the insulin-like growth factor I (IGF-I) potentiates insulin-like actions. Paradoxically, adults with GH deficiency and patients with acromegaly are both predisposed to glucose intolerance and insulin resistance; however, one cannot extrapolate from these pathological conditions to determine the true metabolic roles of GH and IGF-I in glucose homeostasis. Growth hormone also promotes lipolysis, which has been shown to be the principal determinant of its insulin-antagonistic properties; on the other hand, IGF-I, which acts as an insulin sensitizer, does not exert any direct effect on lipolysis or lipogenesis. Under physiological conditions, the insulin-sensitizing effect of IGF-I is evident only after feeding, when the bioavailability of circulating IGF-I is increased. In contrast to supraphysiological GH doses, low doses of GH treatment have been shown to increase circulating IGF-I levels and IGF-I bioavailability and, thus, may theoretically enhance insulin sensitivity without inducing lipolysis. We have recently reported that a fixed administration of a very low GH dose (1.7 μg/kg/day or 0.1 mg/day) improved insulin sensitivity in adults with GH deficiency and increased peripheral glucose uptake in subjects with impaired glucose tolerance and the metabolic syndrome. Our data raise the possibility that this very low GH dose may play a role in maintaining β-cell function and possibly delay the progression to type 2 diabetes in these high-risk patients.",
keywords = "Growth hormone, Growth hormone deficient adults, Insulin sensitivity, Insulin-like growth factor I, Metabolic syndrome",
author = "Yuen, {Kevin C J} and Dunger, {David B.}",
year = "2006",
month = "7",
doi = "10.1016/j.ghir.2006.03.001",
language = "English (US)",
volume = "16",
pages = "55--61",
journal = "Endocrinology and Metabolism, Supplement",
issn = "1096-6374",
publisher = "Churchill Livingstone",
number = "SUPPL.",

}

TY - JOUR

T1 - Impact of treatment with recombinant human GH and IGF-I on visceral adipose tissue and glucose homeostasis in adults

AU - Yuen, Kevin C J

AU - Dunger, David B.

PY - 2006/7

Y1 - 2006/7

N2 - Supraphysiological doses of growth hormone (GH) therapy are generally thought to antagonize the effects of insulin, whereas the insulin-like growth factor I (IGF-I) potentiates insulin-like actions. Paradoxically, adults with GH deficiency and patients with acromegaly are both predisposed to glucose intolerance and insulin resistance; however, one cannot extrapolate from these pathological conditions to determine the true metabolic roles of GH and IGF-I in glucose homeostasis. Growth hormone also promotes lipolysis, which has been shown to be the principal determinant of its insulin-antagonistic properties; on the other hand, IGF-I, which acts as an insulin sensitizer, does not exert any direct effect on lipolysis or lipogenesis. Under physiological conditions, the insulin-sensitizing effect of IGF-I is evident only after feeding, when the bioavailability of circulating IGF-I is increased. In contrast to supraphysiological GH doses, low doses of GH treatment have been shown to increase circulating IGF-I levels and IGF-I bioavailability and, thus, may theoretically enhance insulin sensitivity without inducing lipolysis. We have recently reported that a fixed administration of a very low GH dose (1.7 μg/kg/day or 0.1 mg/day) improved insulin sensitivity in adults with GH deficiency and increased peripheral glucose uptake in subjects with impaired glucose tolerance and the metabolic syndrome. Our data raise the possibility that this very low GH dose may play a role in maintaining β-cell function and possibly delay the progression to type 2 diabetes in these high-risk patients.

AB - Supraphysiological doses of growth hormone (GH) therapy are generally thought to antagonize the effects of insulin, whereas the insulin-like growth factor I (IGF-I) potentiates insulin-like actions. Paradoxically, adults with GH deficiency and patients with acromegaly are both predisposed to glucose intolerance and insulin resistance; however, one cannot extrapolate from these pathological conditions to determine the true metabolic roles of GH and IGF-I in glucose homeostasis. Growth hormone also promotes lipolysis, which has been shown to be the principal determinant of its insulin-antagonistic properties; on the other hand, IGF-I, which acts as an insulin sensitizer, does not exert any direct effect on lipolysis or lipogenesis. Under physiological conditions, the insulin-sensitizing effect of IGF-I is evident only after feeding, when the bioavailability of circulating IGF-I is increased. In contrast to supraphysiological GH doses, low doses of GH treatment have been shown to increase circulating IGF-I levels and IGF-I bioavailability and, thus, may theoretically enhance insulin sensitivity without inducing lipolysis. We have recently reported that a fixed administration of a very low GH dose (1.7 μg/kg/day or 0.1 mg/day) improved insulin sensitivity in adults with GH deficiency and increased peripheral glucose uptake in subjects with impaired glucose tolerance and the metabolic syndrome. Our data raise the possibility that this very low GH dose may play a role in maintaining β-cell function and possibly delay the progression to type 2 diabetes in these high-risk patients.

KW - Growth hormone

KW - Growth hormone deficient adults

KW - Insulin sensitivity

KW - Insulin-like growth factor I

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=33745215422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745215422&partnerID=8YFLogxK

U2 - 10.1016/j.ghir.2006.03.001

DO - 10.1016/j.ghir.2006.03.001

M3 - Article

VL - 16

SP - 55

EP - 61

JO - Endocrinology and Metabolism, Supplement

JF - Endocrinology and Metabolism, Supplement

SN - 1096-6374

IS - SUPPL.

ER -